Suggested Remit: To evaluate the benefits and costs of avalglucosidase alfa within its marketing authorisation for treating Pompe disease for national commissioning by NHS England.
Status Proposed
Process HST
ID number 3737

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
11 September 2020 (10:00) Scoping workshop
14 July 2020 - 11 August 2020 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance